Education
About Us
Working with TipRanks
Follow Us
GoodRx Holdings (GDRX)
NASDAQ:GDRX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.1Last Year’s EPS
0.08Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 11.87%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook with several positive developments such as revenue growth, strong financial performance, and expanding manufacturer solutions. However, challenges like the Rite Aid bankruptcy, pressure on monthly active consumers, and macroeconomic uncertainties present potential setbacks.Company Guidance
During the GoodRx First Quarter 2025 Earnings Call, the company provided guidance for the fiscal year, projecting total revenue between $810 million and $840 million, with anticipated growth of 2% to 6% compared to 2024. The company also slightly increased and narrowed its full-year adjusted EBITDA guidance to a range between $273 million and $287 million, representing 5% to 10% growth from the previous year. In the first quarter, GoodRx reported total revenue of $203 million, a 3% increase from the prior year, and an adjusted EBITDA of $69.8 million, reflecting an 11% year-over-year rise and a margin of 34.4%. GoodRx's prescription transaction revenue and manufacturer solutions revenue grew by 2% and 17%, respectively. The company ended the quarter with $301 million in cash and deployed approximately $100 million to repurchase shares, with $189 million remaining under its repurchase program. The guidance did not incorporate potential impacts from the recent Rite Aid bankruptcy announcement, as Rite Aid is projected to represent less than 5% of GoodRx's 2025 revenue.Revenue Growth and Strong Financial Performance
Total revenue for the first quarter was $203 million, up 3% versus the prior year, with adjusted EBITDA of $69.8 million rising 11%. The company has a strong balance sheet with $301 million in cash and $392.7 million in total liquidity.
Manufacturer Solutions Growth
Manufacturer solutions grew by 17% year-over-year, with an expectation of 20% growth for the full year, driven by expanded partnerships and deeper drug portfolio penetration.
New Leadership Appointments
Wendy Barnes completed her first 100 days as CEO, appointing key leaders like Aaron Crittenden as President of RX Marketplace and Scott Pope as Chief Pharmacy Officer, strengthening the leadership team.
Recognition and Brand Trust
GoodRx was recognized as one of Newsweek and USA Today's 2025 Most Trusted Brands, highlighting its strong consumer trust and brand presence.
---
GDRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GDRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 07, 2025 | $3.79 | $4.24 | +11.87% |
| Feb 27, 2025 | $4.89 | $4.98 | +1.84% |
| Nov 07, 2024 | $6.11 | $5.04 | -17.51% |
| Aug 08, 2024 | $8.61 | $7.01 | -18.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GoodRx Holdings (GDRX) report earnings?
GoodRx Holdings (GDRX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is GoodRx Holdings (GDRX) earnings time?
GoodRx Holdings (GDRX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GDRX EPS forecast?
GDRX EPS forecast for the fiscal quarter 2025 (Q2) is 0.1.
---
